CoChat

Withdrawal of cerivastatin from the world market

Open access
Furberg, Curt D, Pitt, Bertram · 2001 · Trials

The DOI matches its Crossref record; 7 of the 8 references it cites were found in a registry or an index.

Abstract

Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdomyolysis was 10 times more common with cerivastatin than the other five approved statins. We address three important questions raised by this withdrawal. Should we continue to approve drugs on surrogate efficacy? Are all statins interchangeable? Do the benefits outweigh the risks of statins? We conclude that decisions regarding the use of drugs should be based on direct evidence from long-term clinical outcome trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/cvm-2-5-205

Cites

7 of 8 references verified1 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 5

  1. American Heart Association and American College of Cardiology Advisory ACC and AHA reassure patients about statins' effectiveness, safety. Physicians patients urged to discuss concerns side effects and options for lowering cholesterol. News Release August 30, 2001
  2. Fuhrmans V Winslow R Harris G Bayer recall spurs Europe to wide review. Wall Street Journal, August 10, 2001 A3
  3. Division of Drug Marketing Advertising and Communications of the US Food and Drug Administration Warning letter to Novartis Pharmaceuticals Corporation. Re: Lescol (fluvastatin sodium) capsules. January 21, 1999
  4. Division of Drug Marketing Advertising and Communications of the US Food and Drug Administration Warning letter to Pfizer Inc. Re: Lipitor (atorvastatin calcium) tablets. July 12, 2001
  5. Pfeffer MA Keech A Cobbe SM Tonkin A Byington RP Braunwald E Friedman C Sachs FM Prospective Pravastatin Pooling (PPP) project: the tolerability and safety of pravastatin based on a 112,000 patient-year experience in placebo-controlled trials [abstract]. Eur Heart J 2001 22(suppl) 271

Cited by

See all 441

Metadata

Authors
Furberg, C. D., & Pitt, B.
Affiliations
  • Wake Forest University Health Sciences (US)
  • University of Michigan (US)
Corresponding author
Furberg, Curt D
Venue
Trials
Published
2001-09-26
Volume
2
Issue
5
Pages
205-207
ISSN
1745-6215 (ISSN-L)
OpenAlex
W1560686237
Cited by
400
References
7
Citations by year
2026: 4 · 2025: 15 · 2024: 12 · 2023: 24 · 2022: 16 · 2021: 13 · 2020: 15 · 2019: 22 · 2018: 24 · 2017: 15 · 2016: 21 · 2015: 25 · 2014: 19 · 2013: 15 · 2012: 20
FWCI
20.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Trials (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
cerivastatin, drug withdrawal, rhabdomyolysis, statins, gemfibrozil, drug safety, drug approval, risk-benefit assessment, drug interchangeability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Withdrawal of cerivastatin from the world market. https://app.cochat.ai/papers/10.1186/cvm-2-5-205
The paper
Furberg, C. D., & Pitt, B. (2001). Withdrawal of cerivastatin from the world market. Trials. https://doi.org/10.1186/cvm-2-5-205

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.